2018.01.10
An article on API process research in the Chemical R&D Division of the company has been published and is described by one of the authors, Dr. Ikemoto.
http://pubs.acs.org/doi/10.1021/acs.oprd.7b00313
Title: Development of a Practical Synthesis of a Peripherally Selective Noradrenaline Reuptake Inhibitor Possessing a Chiral 6,7-trans-Disubstituted-1,4-oxazepane as a Scaffold
Journal: Org. Process Res. Dev., 2017, 21 (12), pp 2001–2011
Authors: Kazuhisa Ishimoto*, Kotaro Yamaguchi*, Atsushi Nishimoto*, Mika Murabayashi*, and Tomomi Ikemoto** (Takeda Pharmaceutical Company, Ltd., ** SPERA PHARMA , Inc.)
In this article, practical synthesis of a 6,7-disubstituted-1,4-oxazepane intermediate of a compound with peripheral selective noradrenaline reuptake inhibitory activity, in high diastereoselectivity and high optical purity, is reported as an example of drug substance process research (the research was conducted at Pharmaceutical Sciences, Takeda Pharmaceutical Company).
The development of an efficient synthesis method for a novel chiral scaffold, as described in this article, and the technology and experience related to drug substance process R&D is one of the strengths of SPERA PHARMA . We would like to promote drug discovery R&D by solving customer’s synthesis problems and proposing optimal synthesis methods.
page top